
Episode 448: Caremark in 2026 — Where Delaware Draws the Line Between Bad Judgment and Bad Faith
In this episode of Corruption, Crime and Compliance, Michael Volkov examines how Delaware's Caremark doctrine has matured through a recent run of decisions involving Teligent, Regions Financial, and Boeing, all centered on the question of when a board's failure to prevent corporate misconduct crosses from ordinary mismanagement into an actual breach of the duty of loyalty. He walks through Teligent's officer-level oversight failures in FDA compliance, Regions Financial's lesson that a whistleblower investigation without genuine follow-through and remediation doesn't satisfy Caremark's good-faith standard, and the pivotal 2026 Boeing dismissal, where extensive board and committee engagement on safety protected directors even after another serious incident. The episode closes with practical guidance for compliance officers on identifying mission-critical risks, building real escalation and follow-up procedures, and documenting board oversight, since Caremark, as these cases confirm, does not demand perfection, only a good-faith effort to oversee the risks that genuinely matter.
D'autres épisodes de "Corruption Crime & Compliance"



Ne ratez aucun épisode de “Corruption Crime & Compliance” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.








